Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 30 Mar 2019 - 5 Apr 2019
STUDY TYPE:Human Studies, Pharmacology/Drug Development
PAIN TYPE:Migraine/Headache
DATE PUBLISHED: 2019 Jun
JOURNAL:Headache
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30942898?dopt=Abstract
Volume:59
ISSUE:6
We examined the efficacy and safety of galcanezumab after treatment cessation in randomized double-blind, placebo-controlled, migraine prevention studies (EVOLVE-1; EVOLVE-2).
